BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme
By Denny Jacob
BioMarin Pharmaceutical received a subpoena from the U.S. Justice Department for certain documents regarding sponsored testing programs related to vimizim and naglazyme.
The biotechnology company said it has produced the requested documents in response to the subpoena and is cooperating fully, according to a regulatory filing. It added that it is unable to make any assurance regarding the outcome of the investigation by the DOJ and the potential impact such an investigation would have on aspects of the company.
A representative for the DOJ didn't immediately respond to a request for comment.
Vimizim is a treatment of MPS IVA, a lysosomal storage disorder. Naglazyme is a treatment for patients with MPS VI, a life-threatening genetic disease.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 26, 2024 14:23 ET (19:23 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing